Phage Resistance in Multidrug-Resistant Klebsiella pneumoniae ST258 Evolves via Diverse Mutations That Culminate in Impaired Adsorption
- PMID: 31992617
- PMCID: PMC6989104
- DOI: 10.1128/mBio.02530-19
Phage Resistance in Multidrug-Resistant Klebsiella pneumoniae ST258 Evolves via Diverse Mutations That Culminate in Impaired Adsorption
Abstract
The evolution of phage resistance poses an inevitable threat to the efficacy of phage therapy. The strategic selection of phage combinations that impose high genetic barriers to resistance and/or high compensatory fitness costs may mitigate this threat. However, for such a strategy to be effective, the evolution of phage resistance must be sufficiently constrained to be consistent. In this study, we isolated lytic phages capable of infecting a modified Klebsiella pneumoniae clinical isolate and characterized a total of 57 phage-resistant mutants that evolved from their prolonged coculture in vitro Single- and double-phage-resistant mutants were isolated from independently evolved replicate cocultures grown in broth or on plates. Among resistant isolates evolved against the same phage under the same conditions, mutations conferring resistance occurred in different genes, yet in each case, the putative functions of these genes clustered around the synthesis or assembly of specific cell surface structures. All resistant mutants demonstrated impaired phage adsorption, providing a strong indication that these cell surface structures functioned as phage receptors. Combinations of phages targeting different host receptors reduced the incidence of resistance, while, conversely, one three-phage cocktail containing two phages targeting the same receptor increased the incidence of resistance (relative to its two-phage, nonredundant receptor-targeting counterpart). Together, these data suggest that laboratory characterization of phage-resistant mutants is a useful tool to help optimize therapeutic phage selection and cocktail design.IMPORTANCE The therapeutic use of bacteriophage (phage) is garnering renewed interest in the setting of difficult-to-treat infections. Phage resistance is one major limitation of phage therapy; therefore, developing effective strategies to avert or lessen its impact is critical. Characterization of in vitro phage resistance may be an important first step in evaluating the relative likelihood with which phage-resistant populations emerge, the most likely phenotypes of resistant mutants, and the effect of certain phage cocktail combinations in increasing or decreasing the genetic barrier to resistance. If this information confers predictive power in vivo, then routine studies of phage-resistant mutants and their in vitro evolution should be a valuable means for improving the safety and efficacy of phage therapy in humans.
Keywords: bacteriophage cocktails; bacteriophage resistance; bacteriophage therapy.
Figures




Similar articles
-
Characterization of Klebsiella pneumoniae ST11 Isolates and Their Interactions with Lytic Phages.Viruses. 2019 Nov 19;11(11):1080. doi: 10.3390/v11111080. Viruses. 2019. PMID: 31752386 Free PMC article.
-
Phage-mediated virulence loss and antimicrobial susceptibility in carbapenem-resistant Klebsiella pneumoniae.mBio. 2025 Feb 5;16(2):e0295724. doi: 10.1128/mbio.02957-24. Epub 2024 Dec 23. mBio. 2025. PMID: 39714187 Free PMC article.
-
A Smooth-Type, Phage-Resistant Klebsiella pneumoniae Mutant Strain Reveals that OmpC Is Indispensable for Infection by Phage GH-K3.Appl Environ Microbiol. 2018 Oct 17;84(21):e01585-18. doi: 10.1128/AEM.01585-18. Print 2018 Nov 1. Appl Environ Microbiol. 2018. PMID: 30171001 Free PMC article.
-
The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.Virol J. 2024 Aug 19;21(1):191. doi: 10.1186/s12985-024-02450-7. Virol J. 2024. PMID: 39160541 Free PMC article. Review.
-
Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistant Klebsiella pneumoniae.Curr Pharm Des. 2025;31(13):1007-1019. doi: 10.2174/0113816128343976241117183624. Curr Pharm Des. 2025. PMID: 39757682 Review.
Cited by
-
Interruption of Capsular Polysaccharide Biosynthesis Gene wbaZ by Insertion Sequence IS903B Mediates Resistance to a Lytic Phage against ST11 K64 Carbapenem-Resistant Klebsiella pneumoniae.mSphere. 2022 Dec 21;7(6):e0051822. doi: 10.1128/msphere.00518-22. Epub 2022 Nov 15. mSphere. 2022. PMID: 36377881 Free PMC article.
-
Phage resistance formation and fitness costs of hypervirulent Klebsiella pneumoniae mediated by K2 capsule-specific phage and the corresponding mechanisms.Front Microbiol. 2023 Jul 19;14:1156292. doi: 10.3389/fmicb.2023.1156292. eCollection 2023. Front Microbiol. 2023. PMID: 37538841 Free PMC article.
-
Targeted IS-element sequencing uncovers transposition dynamics during selective pressure in enterococci.PLoS Pathog. 2023 Jun 2;19(6):e1011424. doi: 10.1371/journal.ppat.1011424. eCollection 2023 Jun. PLoS Pathog. 2023. PMID: 37267422 Free PMC article.
-
Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-Resistant Klebsiella pneumoniae Treatment.Infect Drug Resist. 2025 Mar 3;18:1253-1262. doi: 10.2147/IDR.S493635. eCollection 2025. Infect Drug Resist. 2025. PMID: 40059940 Free PMC article. Review.
-
Capsule mutations serve as a key strategy of phage resistance evolution of K54 hypervirulent Klebsiella pneumoniae.Commun Biol. 2025 Feb 18;8(1):257. doi: 10.1038/s42003-025-07687-8. Commun Biol. 2025. PMID: 39966630 Free PMC article.
References
-
- Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954-17. doi:10.1128/AAC.00954-17. - DOI - PMC - PubMed
-
- Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. 2019. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730–733. doi:10.1038/s41591-019-0437-z. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical